Central Laboratory Core
中心实验室核心
基本信息
- 批准号:10598378
- 负责人:
- 金额:$ 18.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-03 至 2028-07-31
- 项目状态:未结题
- 来源:
- 关键词:AnusBiological AssayBiological Specimen BanksCDKN2A geneCancer BurdenCancer CenterCharacteristicsClassificationCollaborationsCollectionComplementCountryDNADatabasesDevelopmentDiagnosisEnsureEtiologyEvaluationFutureGenetic TranscriptionGenotypeGerman populationGermanyGoalsGuidelinesHIVHistologyHuman Herpesvirus 4Human Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusImageImmuneImmunofluorescence ImmunologicImmunohistochemistryImmunologic TestsImmunologicsInfrastructureInstitutionInternationalInterventionInvestigationKnowledgeLaboratoriesLeadershipMalignant NeoplasmsMethodologyNCI Center for Cancer ResearchOncologyOropharyngealPathologicPathologistPathologyPatientsPersonsPilot ProjectsPoliciesPreventionProceduresProcessQuality ControlRNAResearchResearch PersonnelResourcesSamplingScienceSerologySiteSlideSouth AfricaSpecimenTechnologyTestingTissue BanksTissuesTumor-infiltrating immune cellsUniversitiesViralViral CancerVulvaZimbabweadjudicationbiobankbiological specimen archivescancer therapydesigndigitalexperienceflexibilitylow and middle-income countriespenistranslational studytumortumor microenvironmentviral detectionvirtualvirus related cancer
项目摘要
PROJECT SUMMARY – CENTRAL LABORATORY CORE
The overarching goal of the Central Laboratory (CL) Core for the Partnership to Assess Viral and Immune
Landscape Intersections with Oncology for People Living with HIV (PAVILION) is to provide centralized
biobanking and virologic and immunologic assessment of well annotated biospecimens in support of the
proposed translational studies as well as future PAVILION pilot projects. The CL Core will be co-led by three
exceptional investigators, Drs. Johann Schneider (South Africa), Zvavahera (Mike) Chirenje (Zimbabwe), and
Tim Waterboer (Germany), who have complementary expertise. The CL Co-Leaders have designed a robust yet
flexible pipeline and range of analytical methodologies that builds upon the infrastructure and long-term
international collaborations established by the PAVILION partnering investigators in South Africa, Zimbabwe,
the US, and Germany. The CL Core purposefully pairs this unique expertise with established laboratories in the
low- and middle-income country (LMIC) partner countries to efficiently advance knowledge related to tumor and
patient characteristics. This knowledge can then inform the development of effective prevention and cancer
treatment interventions to reduce the burden of cancer for people living with HIV (PLWH) in LMICs
disproportionately impacted by HIV. To achieve the overarching goal, the CL Core will provide centralized,
research-quality pathology evaluation for endpoint adjudication of collected tissues, DNA and RNA extraction,
HPV and EBV detection and genotyping, RNA expression analysis, multiplex viral serology assessment, and
immunological evaluation of the tumor microenvironment for the proposed and future projects. These activities
are organized into the following Aims:
Aim 1: Serve as a centralized biobanking resource in South Africa and Zimbabwe for the collection,
processing, and storage of biospecimens in support of PAVILION studies This aim provides biobanking
of high-burden and under-researched viral cancers in LMIC settings, including non-cervical HPV-associated
cancers (anal, oropharyngeal, penile, and vulvar) and conjunctival cancer, with a suspected but as of yet
unidentified viral etiology amongst PLWH.
Aim 2: Provide centralized virologic and immunologic testing of biospecimens in support of proposed
and future PAVILION studies This aim provides centralized viral and immunologic testing of banked specimens
in support of proposed and future study aims through a robust set of analytical methodologies across four
PAVILION partnering institutions, including LMIC and non-LMIC sites.
Aim 3: Provide centralized expert pathology in support of proposed and future PAVILION studies This
aim provides comprehensive and expert centralized pathology adjudication of banked tissue specimens in
support of the proposed translational studies and future Developmental Core pilot studies.
项目总结-中心实验室核心
中心实验室(CL)评估病毒和免疫合作伙伴关系核心的总体目标
艾滋病病毒感染者肿瘤学景观交叉点(PAVILION)将提供集中的
对注释良好的生物标本进行生物库、病毒学和免疫学评估,以支持
建议的转化研究以及未来的PAVILION试点项目。CL核心将由三个人共同领导
杰出的研究人员Johann Schneider博士(南非)、Zvavahera(Mike)Chirenje博士(津巴布韦)和
Tim Waterboer(德国),他们具有互补的专门知识。CL联合领导人设计了一个强大的,
建立在基础设施和长期基础上的灵活渠道和一系列分析方法
PAVILION与南非,津巴布韦,
美国和德国。CL Core有目的地将这种独特的专业知识与
低收入和中等收入国家(LMIC)伙伴国家有效地推进与肿瘤相关的知识,
患者特征。这些知识可以为有效预防和癌症的发展提供信息
治疗干预措施,以减少中低收入国家艾滋病毒感染者的癌症负担
受艾滋病毒的严重影响。为了实现总体目标,CL核心将提供集中的,
研究质量病理学评价,用于采集组织的终点判定、DNA和RNA提取,
HPV和EBV检测和基因分型,RNA表达分析,多重病毒血清学评估,以及
肿瘤微环境的免疫学评估,用于拟议和未来的项目。这些活动
组织成以下目标:
目标1:作为南非和津巴布韦的集中生物库资源,
处理和储存生物样本以支持PAVILION研究
LMIC环境中高负担和研究不足的病毒性癌症,包括非宫颈HPV相关的
癌症(肛门,口咽,阴茎和外阴)和结膜癌,怀疑但截至目前
艾滋病毒感染者中病毒病因不明。
目标2:提供生物标本的集中病毒学和免疫学检测,以支持拟议的
和未来的PAVILION研究这一目标提供了集中的病毒和免疫学检测库标本
通过一套强有力的分析方法,支持拟议的和未来的研究目标,
PAVILION合作机构,包括LMIC和非LMIC站点。
目的3:提供集中的专家病理学,以支持拟议和未来的PAVILION研究。
aim为库存组织标本提供全面和专家集中的病理学裁定,
支持拟议的转化研究和未来的发展核心试点研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Johann Wilhelm Schneider其他文献
Johann Wilhelm Schneider的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Establishment of a new biological assay using Hydra nematocyst deployment
利用水螅刺丝囊部署建立新的生物测定方法
- 批准号:
520728-2017 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
University Undergraduate Student Research Awards
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10368760 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
10669539 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9570142 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER) AFTER RADIOLOGICAL AND NUCLEAR EVENTS.
用于确定放射和核事件后组织特异性吸收电离辐射剂量(生物剂量计)的护理点生物测定。
- 批准号:
9915803 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
COVID-19 Supplemental work: POINT-OF-CARE BIOLOGICAL ASSAY FOR DETERMINING TISSUE-SPECIFIC ABSORBED IONIZING RADIATION DOSE (BIODOSIMETER).
COVID-19 补充工作:用于确定组织特异性吸收电离辐射剂量的护理点生物测定(生物剂量计)。
- 批准号:
10259999 - 财政年份:2017
- 资助金额:
$ 18.71万 - 项目类别:
Drug discovery based on a new biological assay system using Yeast knock-out strain collection
基于使用酵母敲除菌株收集的新生物测定系统的药物发现
- 批准号:
21580130 - 财政年份:2009
- 资助金额:
$ 18.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2005
- 资助金额:
$ 18.71万 - 项目类别:
Postdoctoral Fellowships
Machine learning for automatic gene annotation using high-throughput biological assay data
使用高通量生物测定数据进行自动基因注释的机器学习
- 批准号:
300985-2004 - 财政年份:2004
- 资助金额:
$ 18.71万 - 项目类别:
Postdoctoral Fellowships